{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:54:27Z","timestamp":1791323667199,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jvir.2026.108960","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:04:06Z","timestamp":1784214246000},"page":"108960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I Dose-Escalation Study Combining Irinotecan-Loaded Drug-Eluting Bead Chemoembolization with Yttrium-90 Glass Microsphere Radioembolization in Colorectal Liver Metastases (DEBIR90Y)"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-6594","authenticated-orcid":false,"given":"Li Shen","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alsultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-655X","authenticated-orcid":false,"given":"Maarten L.J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Bruijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"Arthur J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8751-748X","authenticated-orcid":false,"given":"Kirk D.","family":"Fowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-3823","authenticated-orcid":false,"given":"Guus M.","family":"Bol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-9790","authenticated-orcid":false,"given":"Marnix G.E.H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2026.108960_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jvir.2026.108960_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2026.108960_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(23)00219-X","article-title":"First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group","volume":"24","author":"Bond","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/path.1700450211","article-title":"The blood supply of newly developed epithelial tissue in the liver","volume":"45","author":"Wright","year":"1937","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.jvir.2026.108960_bib7","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.21873\/anticanres.12598","article-title":"SN-38 acts as a radiosensitizer for colorectal cancer by inhibiting the radiation-induced up-regulation of HIF-1\u03b1","volume":"38","author":"Okuno","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jvir.2026.108960_bib8","first-page":"22","article-title":"Irinotecan and radiation in combined-modality therapy for solid tumors","volume":"15","author":"Choy","year":"2001","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jvir.2026.108960_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jvir.2018.06.023","article-title":"Pilot study comparing systemic and tissue pharmacokinetics of irinotecan and metabolites after hepatic drug-eluting chemoembolization","volume":"30","author":"Levy","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2026.108960_bib10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s00270-020-02538-x","article-title":"Feasibility of combination intra-arterial yttrium-90 and irinotecan microspheres in the VX2 rabbit model","volume":"43","author":"Gordon","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2026.108960_bib11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jvir.2026.108960_bib12","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1007\/s00259-025-07229-8","volume":"52","author":"Lam","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jvir.2026.108960_bib13","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","article-title":"Dose-response and dose-toxicity relationships for glass 90Y radioembolization in patients with liver metastases from colorectal cancer","volume":"62","author":"Alsultan","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jvir.2026.108960_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2026.108960_bib15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2026.108960_bib17","first-page":"27","article-title":"Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy","volume":"13","author":"Sofocleous","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jvir.2026.108960_bib18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.21037\/jgo.2016.08.04","article-title":"Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study","volume":"7","author":"Fidelman","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2478\/raon-2024-0023","article-title":"Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases","volume":"58","author":"Sljivic","year":"2024","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2013.12.040","article-title":"Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization","volume":"88","author":"Hickey","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2026.108960_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104292","article-title":"Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study","volume":"10","author":"Arnold","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jvir.2026.108960_bib21","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.21873\/anticanres.16545","article-title":"Prognostic value of TACE with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with liver metastases from unresectable colorectal cancer","volume":"43","author":"Ishikawa","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jvir.2026.108960_bib22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2967\/jnumed.115.166082","article-title":"90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study","volume":"57","author":"Hickey","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jvir.2026.108960_bib23","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00432-013-1564-4","article-title":"A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases","volume":"140","author":"Saxena","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.suronc.2017.05.003","article-title":"Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review","volume":"26","author":"Akinwande","year":"2017","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jvir.2026.108960_bib25","first-page":"1097","article-title":"Transarterial radioembolization in the TACOME trial: dosimetric analysis and clinical features in predicting response and overall survival","volume":"66","author":"Soydal","year":"2025","journal-title":"J Nucl Med"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044326009711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:47:57Z","timestamp":1791323277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044326009711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1051044326009711"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108960","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Dose-Escalation Study Combining Irinotecan-Loaded Drug-Eluting Bead Chemoembolization with Yttrium-90 Glass Microsphere Radioembolization in Colorectal Liver Metastases (DEBIR90Y)","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2026.108960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR 2026 .","name":"copyright","label":"Copyright"}],"article-number":"108960"}}